Dicerna Selling $70M In Preferred Stock To PE Group
Dicerna Pharmaceuticals Inc., a developer of genetic treatments for chronic liver, cardiovascular and viral infectious diseases, on Thursday said that it has agreed to sell a syndicate of private equity investors...To view the full article, register now.
Already a subscriber? Click here to view full article